BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest Update

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was the recipient of a significant drop in short interest in December. As of December 15th, there was short interest totalling 17,290,000 shares, a drop of 10.7% from the November 30th total of 19,360,000 shares. Based on an average daily volume of 1,990,000 shares, the days-to-cover ratio is presently 8.7 days.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BCRX. Barclays upped their price objective on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Finally, Needham & Company LLC restated a “buy” rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $15.60.

Institutional Trading of BioCryst Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Deerfield Management Company L.P. Series C lifted its holdings in shares of BioCryst Pharmaceuticals by 62.9% during the second quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company’s stock worth $50,279,000 after buying an additional 3,140,804 shares in the last quarter. Geode Capital Management LLC increased its position in BioCryst Pharmaceuticals by 2.7% during the third quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock worth $36,776,000 after acquiring an additional 127,708 shares during the period. Fisher Asset Management LLC raised its stake in BioCryst Pharmaceuticals by 16.9% in the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock worth $25,369,000 after purchasing an additional 481,359 shares in the last quarter. Two Sigma Advisers LP boosted its holdings in BioCryst Pharmaceuticals by 13.6% in the 3rd quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company’s stock valued at $16,576,000 after purchasing an additional 261,500 shares during the period. Finally, Rice Hall James & Associates LLC grew its position in shares of BioCryst Pharmaceuticals by 4.0% during the 3rd quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock worth $16,444,000 after purchasing an additional 84,102 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Stock Down 0.1 %

Shares of NASDAQ BCRX traded down $0.01 during mid-day trading on Wednesday, reaching $7.52. 1,513,767 shares of the company were exchanged, compared to its average volume of 2,813,235. The stock has a market capitalization of $1.56 billion, a P/E ratio of -12.33 and a beta of 1.79. The company’s 50-day simple moving average is $7.63 and its 200-day simple moving average is $7.49. BioCryst Pharmaceuticals has a twelve month low of $4.03 and a twelve month high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). The company had revenue of $117.10 million for the quarter, compared to analyst estimates of $113.99 million. During the same quarter last year, the business earned ($0.19) earnings per share. The company’s revenue was up 35.1% on a year-over-year basis. As a group, equities research analysts expect that BioCryst Pharmaceuticals will post -0.38 EPS for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.